Solventum (NYSE:SOLV) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Solventum (NYSE:SOLV) released its earnings results on Thursday. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.11, FiscalAI reports. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter last year, the company earned $1.50 earnings per share. The firm’s revenue was down 7.0% on a year-over-year basis.

Here are the key takeaways from Solventum’s conference call:

• Q3 sales were $1.95 billion, down 7% reported and 2.8% organically, including a 630-basis-point headwind from the planned reversal of ERP-related advance orders. Management said normalized organic growth was about 4%; EPS was $1.45, including an estimated $0.35 impact from the timing reversal.
• Solventum raised its 2026 outlook, now expecting organic sales growth toward the high end of its 2.5%–3% range and EPS of $7.20–$7.30, up from $7.10–$7.20. Operating margin is expected toward the high end of its 22.2%–22.7% range.
• The company completed its largest ERP cutover and said its separation from 3M is more than 90% complete, with the remaining transition services expected to end by the close of 2027. A renegotiated supply agreement also removes a previously anticipated 100-basis-point gross-margin headwind beginning in 2027; management expects separation costs to step down, supporting free cash flow.
• Solventum is evaluating a sale or spin-off of Health Information Systems (HIS), with timing and structure still undecided. Management estimates the separation would cause about 400 basis points of annualized net operating margin dilution, though it expects to use proceeds first to pay down debt and then return most remaining proceeds to shareholders.
• Management highlighted growth opportunities from underpenetrated products, new launches, and acquisitions, including V.A.C. wound therapy and Acera. Acera grew 35% and had its best quarter on record, while the company said its combined-use clearance for Restrata and V.A.C. enables joint marketing.

Solventum Price Performance

SOLV stock traded down $2.44 during trading on Thursday, hitting $86.91. The company had a trading volume of 1,880,645 shares, compared to its average volume of 1,173,033. The company has a fifty day moving average price of $87.75 and a two-hundred day moving average price of $78.64. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The company has a market cap of $14.79 billion, a P/E ratio of 12.59, a P/E/G ratio of 1.30 and a beta of 0.69. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $94.16.

Key Stories Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Adjusted earnings were $1.45 per share, ahead of analyst estimates of $1.34–$1.35, and revenue of $1.95 billion also topped expectations. Solventum raised its FY2026 adjusted EPS outlook to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Reported sales fell 7.0% year over year, while organic sales declined 2.8%. The company attributed the organic decrease partly to a 630-basis-point impact from customers’ advance orders in the prior quarter ahead of an ERP system cutover. Coverage also described the quarter as a loss on a reported basis, despite the adjusted earnings beat. Solventum Posts Q3 Loss; Raises FY26 Adjusted EPS Outlook
• Negative Sentiment: Higher raw-material costs remain a concern, potentially tempering the benefit of growth investments and cost-saving efforts. Here’s Why You Should Hold Solventum Stock in Your Portfolio for Now

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Mizuho set a $113.00 price target on Solventum in a report on Thursday, August 6th. UBS Group lifted their price objective on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Jefferies Financial Group restated a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. BMO Capital Markets initiated coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 target price for the company. Finally, Stifel Nicolaus raised their target price on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.55.

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.